(ADXN) Addex Therapeutics - Ratings and Ratios

Addex Therapeutics Ltd (NASDAQ:ADXN) is a Swiss-based biotechnology company specializing in the discovery, development, and commercialization of small-molecule pharmaceuticals targeting central nervous system (CNS) disorders. The company focuses on G-protein coupled receptors (GPCRs) and enzymes, leveraging its expertise in allosteric modulation to develop novel therapeutics. Its lead pipeline includes Dipraglurant, an mGluR5 negative allosteric modulator (NAM) for Parkinsons disease levodopa-induced dyskinesia (PD-LID), dystonia, and post-stroke/TBI recovery. The compound has shown promise in clinical trials, addressing a significant unmet need in movement disorders. Additionally, the company is advancing ADX71149, a metabotropic glutamate receptor subtype 2 (mGlu2) positive allosteric modulator (PAM), for epilepsy, and GABAB PAM for pain, anxiety, overactive bladder, addiction, and substance use disorder. These programs highlight the companys focus on addressing diverse CNS conditions with high prevalence and limited treatment options.

Addex has established strategic partnerships to accelerate its pipeline. It collaborates with Janssen Pharmaceuticals Inc. under a license and collaboration agreement to develop novel mGlu2 PAM compounds for CNS diseases. Another partnership with Indivior PLC focuses on GABAB PAM compounds for addiction and CNS disorders. The company also works with The Charcot-Marie-Tooth Association to explore GABAB PAM compounds in preclinical models of CMT1A, expanding its neurology-focused research efforts. These collaborations underscore Addexs commitment to innovation and external validation of its pipeline.

From a financial perspective, Addex Therapeutics Ltd operates with a market capitalization of $9.09M USD, reflecting its small-cap status. The companys price-to-book (P/B) ratio of 0.73 suggests undervaluation relative to its book value, while the price-to-sales (P/S) ratio of 15.34 indicates a premium valuation relative to revenue. The return on equity (RoE) of 48.86% highlights efficient equity utilization, though the absence of positive P/E ratios signals the companys pre-profitability stage.

Technically, ADXN shares are trading at $7.70 with a 20-day average volume of 7,051. The stock is currently below its 20-day and 50-day simple moving averages (SMA) of $7.77 and $7.78, respectively, but remains above its 200-day SMA of $8.66. The average true range (ATR) of 0.74 indicates moderate volatility. Over the next three months, the stock may face resistance at the 200-day SMA level, with potential selling pressure if it fails to break above $8.66. The low average volume suggests limited liquidity, which could amplify price movements in response to news or catalysts.